Leerink Partnrs Issues Negative Forecast for TMO Earnings

Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) - Equities researchers at Leerink Partnrs dropped their Q4 2024 earnings per share estimates for Thermo Fisher Scientific in a report released on Wednesday, October 23rd. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will post earnings per share of $5.97 for the quarter, down from their prior estimate of $6.04. The consensus estimate for Thermo Fisher Scientific's current full-year earnings is $21.72 per share. Leerink Partnrs also issued estimates for Thermo Fisher Scientific's Q1 2025 earnings at $5.59 EPS, Q2 2025 earnings at $5.77 EPS, Q3 2025 earnings at $5.79 EPS, Q4 2025 earnings at $6.67 EPS, FY2025 earnings at $23.81 EPS and FY2026 earnings at $26.49 EPS.

TMO has been the subject of a number of other reports. Sanford C. Bernstein reduced their price target on shares of Thermo Fisher Scientific from $625.00 to $620.00 and set a "market perform" rating for the company in a research report on Thursday. Royal Bank of Canada lowered their target price on Thermo Fisher Scientific from $767.00 to $718.00 and set an "outperform" rating on the stock in a research note on Thursday. Stephens started coverage on Thermo Fisher Scientific in a report on Tuesday, October 1st. They set an "overweight" rating and a $680.00 price target for the company. TD Cowen upped their price objective on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a research report on Tuesday. Finally, Wells Fargo & Company cut their price target on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an "overweight" rating for the company in a report on Thursday. Five analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $649.33.

Thermo Fisher Scientific Stock Down 0.5 %

TMO traded down $3.00 on Friday, reaching $554.38. The company's stock had a trading volume of 1,086,281 shares, compared to its average volume of 1,467,407. The company has a market capitalization of $211.77 billion, a price-to-earnings ratio of 34.72, a P/E/G ratio of 3.75 and a beta of 0.77. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific has a fifty-two week low of $420.21 and a fifty-two week high of $627.88. The stock has a 50 day moving average of $606.12 and a two-hundred day moving average of $584.21.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating analysts' consensus estimates of $5.25 by $0.03. The company had revenue of $10.60 billion for the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The company's quarterly revenue was up .2% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.69 EPS.

Hedge Funds Weigh In On Thermo Fisher Scientific

A number of hedge funds have recently made changes to their positions in the business. Signature Resources Capital Management LLC boosted its stake in shares of Thermo Fisher Scientific by 318.2% in the second quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company's stock valued at $25,000 after purchasing an additional 35 shares during the period. New Millennium Group LLC purchased a new stake in shares of Thermo Fisher Scientific during the second quarter worth about $29,000. Stephens Consulting LLC lifted its stake in shares of Thermo Fisher Scientific by 116.0% in the second quarter. Stephens Consulting LLC now owns 54 shares of the medical research company's stock worth $30,000 after acquiring an additional 29 shares in the last quarter. Headlands Technologies LLC acquired a new stake in Thermo Fisher Scientific during the 1st quarter valued at approximately $32,000. Finally, Bank & Trust Co purchased a new stake in Thermo Fisher Scientific during the 2nd quarter worth approximately $33,000. Hedge funds and other institutional investors own 89.23% of the company's stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 6,300 shares of Thermo Fisher Scientific stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $602.09, for a total value of $3,793,167.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at $74,548,375.44. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, CEO Marc N. Casper sold 6,300 shares of the stock in a transaction on Monday, July 29th. The stock was sold at an average price of $602.09, for a total value of $3,793,167.00. Following the transaction, the chief executive officer now directly owns 123,816 shares of the company's stock, valued at approximately $74,548,375.44. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total value of $6,172,100.00. Following the sale, the chief executive officer now owns 123,816 shares of the company's stock, valued at $76,420,473.36. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.